AI Structured Summary
Not yet generated for this judgment
Judgment
Prathiba M. Singh, J. (Oral)
This hearing has been done through hybrid mode.
Directions in CONT.CAS(C) 678/2024 & CONT.CAS(C) 687/2024
Vide orders dated 22nd July, 2024, and 1st August, 2024, this Court directed AIIMS to take appropriate steps for conducting a detailed consultation with the child, and to process the MRI reports expeditiously.
The father of the Petitioner is present. It is submitted that the child has still to undergo certain tests at ICH, Chennai, and the reports have still to be submitted to AIIMS for further examination.
In view of the above, these two matters are not to be treated as part-heard, and are released to the Roster Bench.
List before the Roster Bench on 18th September, 2024.
Compliance of directions contained in order dated 1st August, 2024
Vide order dated 1st August, 2024, this Court directed Dr. Kabra to place a request for the release of next dose of treatment for the 14 patients diagnosed with DMD.
Today, it is informed to the Court by Mr. Tanveer Oberoi, ld. Counsel for AIIMS that letter to the Ministry of Health in terms of the order dated 1st August, 2024, has been communicated.
Let the Respondent-Union of India inform the Court regarding the steps taken on the next date of hearing.
Directions qua Roche and Sarepta
On 21st August, 2024, this Court directed both M/s. Sarepta Therapeutics and M/s. Roche to place on record a chart, inter alia, giving details of pricing of their respective products.
Today, ld. Sr. Counsel Mr. Saurabh Kirpal submits that the affidavit in terms of orders dated 1st August, 2024, and 21st August, 2024 shall be handed over to the Court by the next date of hearing.
Let both M/s. Sarepta Therapeutics and M/s. Roche hand over the same to the Court in a sealed cover on the next date of hearing.
Additionally, by the next date of hearing, M/s. Sarepta shall place on record a chart detailing:
Details of the distributor(s) in India, if any, of drugs manufactured and sold by M/s. Sarepta Therapeutics
Standard Operating Procedure (SOP) for establishing the manner in which drugs for DMD could be produced, procured, and distributed to patients in India. The SOP should also lay down time-lines for each step for procurement and distribution of medicines.
Final Submissions
Today, on behalf of the Petitioners, the following counsels have concluded their oral submissions:
Ld. Sr. Counsel Sidharth Luthra in W.P.(C) 4539/2023
Ld. Counsel Mr. Ashok Aggarwal for various Petitioners
Ld. Counsel Mr. Aditya Chatterjee appeared virtually in W.P.(C) 3662/2021
Ld. Counsel Mr. Rohin Bhatt in W.P.(C) 11610/2017
Ld. Counsel Ms. Purva Chugh in W.P.(C) 2614/2023
On behalf of AIIMS, ld. Counsel Mr. Tanveer Oberoi, has also concluded his submissions.
On behalf of M/s. Roche, ld. Sr. Counsel Mr. Darpan Wadhwa, and ld. Counsel Mr. Pravin Anand made their submissions, and for M/s. Sarepta Therapeutics, ld. Sr. Counsel Mr. Saurabh Kirpal has made submissions.
Mr. Kirtiman Singh, ld. CGSC under instructions from Mr. Swarnendu Singha (Under Secretary, MoH&FW), has also concluded his submissions.
Parties who wish to hand over their written submissions, are free to do so within a period of one week. Submissions shall be handed over on the next date of hearing.
Oral submissions stand concluded.
List only for the purpose of receiving written submissions on 9th September, 2024 at 4:00 pm.